Founding Chief Executive Officer
Prior to Sigilon Therapeutics, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. He has also served as President and Chief Executive Officer of Antares Pharma as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton has held senior leadership roles at SkyePharma, Eurand International, Penwest Pharmaceuticals, Abbott Laboratories as well as Merck and Sharp & Dohme (Merck & Co.) Dr. Wotton graduated B.Pharm (Hons) from the University of London, holds an M.B.A. from Kingston Business School and received a Ph.D. from the University of Nottingham. Dr Wotton was the EY Entrepreneur of the Year Regional Winner Life Sciences 2014.